Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

20081,636 citationsJournal Articlebronze Open Access

Authors

Carsten Bokemeyer · Universität Hamburg

Igor Bondarenko · Universität Hamburg

Anatoly Makhson · Universität Hamburg

J. T. Hartmann · Universität Hamburg

Jorge Aparicio · Universität Hamburg

Filippo de Braud · Universität Hamburg

S. Donea ·

Abstract

KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 27, Issue 5, pp. 663-671

DOI: 10.1200/jco.2008.20.8397

Field-Weighted Citation Impact: 70.40